Panel defers decision on CEA-Scan:
This article was originally published in Clinica
Executive Summary
The US FDA's oncologic drugs advisory panel has deferred a decision on Immunomedics' colorectal cancer imaging agent CEA-Scan. The panel also recommended that the product be reviewed by the medical imaging drugs advisory committee with the help of selected oncology consultants. It also recommended that Immunomedics and the FDA resolve differences concerning data and image interpretation before resubmission.